


Email: customerservice@vectorlabs.com

Telephone: (650) 697-3600

GOAT ANTI-LRRK2 / PARK8 (NEAR C TERMINUS) ANTIBODY

SKU: EB06550



SPECIFICATIONS

Formulation Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

Unit Size 100 µg

Aliquot and store at -20°C. Minimize freezing and thawing.

Synonym /

Parkinson disease (autosomal dominant) 8|dardarin|leucine-rich repeat kinase

Alias 2|DKFZp434H2111|FLJ45829|ROCO2|PARK8|LRRK2 **Names**

Usage Immunofluorescence: Strong expression of the protein seen in the vesicles of A431 cells

Summary and in the vesicles and nuclei of A549 cells. Recommended concentration: 10µg/ml.

Accession

NP_940980.3

Blocking EBP06550

Peptide





Email: customerservice@vectorlabs.com

Telephone: (650) 697-3600

Peptide with sequence CELAEKMRRTSV, from the internal region (near the C Terminus) of the protein sequence **Immunogen** according to NP 940980.3.

Peptide Sequence

CELAEKMRRTSV

Purification Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography

Method using the immunizing peptide.

Shipping Instructions

Refrigerated

Predicted

Human **Species**

Reactive

Human

Species Human

120892 Gene ID

Product

Grade

https://prod-vector-labs-pimcore-assets.s3.us-east-1.amazonaws.com/assets/products/image/elite medium.png

ELISA

Detection Antibody detection limit dilution 1:128000.

Limit

Not yet tested - our routine western blotting protocol does not allow for the detection of proteins >250kDa Western (calculated MWt of approx. 286kDa according to NP 940980.3). However, customer testing has shown bands Blot

at >250kDa + 140kDa, which has been observed by other commercial sources of LRRK2 antibodies.

Application

Pep-ELISA, IF **Type**

SELECTED REFERENCES

[{"pmid": 19640926, "intro": "This antibody (previous batch) has been successfully used in IEM:", "title": "LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model.", "author": "Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, Wade-Martins R.", "journal": "Hum Mol Genet. 2009 Nov 1;18(21):4022-34."}, {"pmid": 36219522, "intro": "This antibody has been successfully used in the following paper:", "title": "LRRK2 expression in normal and pathologic human gut and in rodent enteric neural cell lines.", "author": "Adrien De Guilhem De Lataillade, Martial Caillaud, Thibauld Oullier, Philippe Naveilhan, Carolina Pellegrini, Eduardo Tolosa, Michel Neunlist, Malvyne Rolli-Derkinderen, Ellen Gelpi, Pascal Derkinderen", "journal": "J Neurochem. 2023 Jan;164(2):193-209."}, {"pmid": 17971075, "intro": "This antibody (previous batch) has been successfully used in WB and IHC on Human:", "title": "LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease.", "author": "Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R.", "journal": "Neuropathol Appl Neurobiol. 2007 Oct 26."}, {"pmid": 21696411, "intro": "This antibody (previous batch) has been successfully used in ICC on Human:", "title": "LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: A morphological and quantitative study.", "author": "Sharma S, Bandopadhyay R, Lashley T,







Renton AE, Kingsbury AE, Kumaran R, Kallis C, Vilariño-Güell C, O'Sullivan SS, Lees AJ, Revesz T, Wood NW, Holton JL.", "journal": "Neuropathol Appl Neurobiol. 2011 Jun 23."}]

GALLERY IMAGES

